AMH Equity Ltd Has $1.88 Million Stock Holdings in Health Catalyst, Inc. $HCAT

AMH Equity Ltd boosted its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 54.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 660,000 shares of the company’s stock after buying an additional 232,851 shares during the quarter. Health Catalyst makes up 2.3% of AMH Equity Ltd’s holdings, making the stock its 11th biggest holding. AMH Equity Ltd owned approximately 0.94% of Health Catalyst worth $1,881,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Cresset Asset Management LLC bought a new position in Health Catalyst in the 2nd quarter valued at about $39,000. Divergent Planning LLC bought a new position in shares of Health Catalyst in the second quarter valued at approximately $45,000. Focus Partners Wealth bought a new position in shares of Health Catalyst in the first quarter valued at approximately $46,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Health Catalyst during the second quarter valued at approximately $73,000. Finally, The Manufacturers Life Insurance Company raised its position in Health Catalyst by 19.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock valued at $100,000 after buying an additional 4,341 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Stifel Nicolaus dropped their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Health Catalyst in a report on Tuesday, October 7th. Wells Fargo & Company dropped their price target on Health Catalyst from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, William Blair reissued an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.32.

Health Catalyst Price Performance

HCAT stock opened at $2.31 on Friday. The firm has a market cap of $163.39 million, a P/E ratio of -1.45 and a beta of 1.69. The firm’s fifty day moving average is $2.48 and its 200 day moving average is $3.02. Health Catalyst, Inc. has a 52 week low of $2.02 and a 52 week high of $5.93. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Monday, November 10th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. Health Catalyst had a negative net margin of 34.05% and a negative return on equity of 6.67%. The company had revenue of $76.32 million during the quarter, compared to analyst estimates of $75.05 million. Research analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Insider Transactions at Health Catalyst

In other news, Director Julie Larson-Green sold 47,997 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $2.67, for a total transaction of $128,151.99. Following the completion of the transaction, the director directly owned 73,573 shares in the company, valued at $196,439.91. This trade represents a 39.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Landry sold 27,425 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $2.64, for a total value of $72,402.00. Following the completion of the transaction, the general counsel owned 100,000 shares of the company’s stock, valued at $264,000. This represents a 21.52% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.